Document Detail


Rapid detection of BCR-ABL fusion genes using a novel combined LUX primer, in-cell RT-PCR and flow cytometric method.
MedLine Citation:
PMID:  17846772     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Currently, quantitative and semiquantitative assays for minimal residual disease detection include fluorescence in situ hybridisation, multiparameter flow cytometric immunophenotyping and real-time quantitative polymerase chain reaction (RQ-PCR). We have developed a new approach to detect hybrid breakpoint cluster region and Abelson proto-oncogene (BCR-ABL) transcripts inside suspension cells using in situ RT-PCR and light upon extension (LUX) primer, followed by rapid quantitative analysis with flow cytometry. After cellular permeabilization and fixation of single cell suspension, the neoplastic mRNA was reverse transcribed and amplified by PCR with LUX primer. The results demonstrated that a strong positive yellow-green signal was observed in 99-100% cells of K562 cell line, only the red nucleus was detected in NB4 cell line and normal controls. The technique has been utilised to study 12 patients with chronic myeloid leukemia, and the results were compared with those of BCR-ABL fusion mRNA by RT-PCR and BCR-ABL fusion gene of the interphase cells by fluorescence in situ hybridization (FISH). In the five diagnosed patients, 90-98% cells were strongly positive. Four patients, including three patients treated with interferon-alpha and hydroxyurea and one patient treated with imatinib mesylate, had 26-82.5% positive cells. Three patients treated with imatinib mesylate were negative. The in situ RT-PCR results demonstrated complete concordance with the results of I-FISH and RT-PCR. A fluorescence signal was detectable at 1/10(4) cells and became negative below this threshold with flow cytometry. The results of the present study suggest that (1) LUX primers can be used to efficiently detect BCR-ABL fusion mRNA by in-cell RT-PCR; (2) the novel technique is a specific and sensitive way of detecting fusion gene with potential clinical usefulness.
Authors:
Yan Shi; Li-Zhen Li; Jian-Zhi Sun; Ti Zhang; Jun Peng; Cong-Gao Xu
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-09-11
Journal Detail:
Title:  Annals of hematology     Volume:  87     ISSN:  1432-0584     ISO Abbreviation:  Ann. Hematol.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-11-21     Completed Date:  2008-04-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  35-41     Citation Subset:  IM    
Affiliation:
Department of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Line, Tumor
DNA Primers / genetics*
Flow Cytometry / methods*
Fusion Proteins, bcr-abl / analysis*,  genetics*
Humans
In Situ Hybridization, Fluorescence
Light*
Reverse Transcriptase Polymerase Chain Reaction / methods*
Time Factors
Chemical
Reg. No./Substance:
0/DNA Primers; 0/Fusion Proteins, bcr-abl

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-alpha-methyl-tyrosi...
Next Document:  Infection and glomerulonephritis.